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TO THE EDITOR
Topical preparations containing thymus-
derived protein extracts have long been
claimed to stimulate human hair growth
(Renner et al., 1986; Sawaya and Sha-
piro, 2000), but there is still no convin-
cing evidence available that they really
modulate human hair growth. Despite
their historical name, most thymic pep-
tides (TPs), such as thymosin b4 (TB4),
prothymosin alpha (PTMA), and thymulin
(TYL), are much more widely distributed
than in the thymic epithelium where they
were first identified (Kato et al., 1981;
Moll et al., 1996; Folch et al., 2010;
Supplementary Information S1 online).
The PTMA gene is prominently expressed
in many rodent tissues (Moll et al., 1996),
including fetal murine hair follicles (HFs).
PTMA is involved in many cellular
processes such as apoptosis, chromatin
remodeling, and transcriptional regula-
tion (reviewed in Hannappel and Huff
(2003)); Supplementary Information S1
online). TYL has been claimed to be
thymus specific, although TYL immuno-
reactivity has also been reported in
murine epidermis and skin appendages
(Kato et al., 1981) and in murine spleen
(Folch et al., 2010). Interactions between
TYL and the neuroendocrine system have
been reported to lead to a release of
prolactin, thyrotropin, and ACTH (Hadley
et al., 1997; Brown et al., 1998). As these
neurohormones are well appreciated as
regulators of human HF growth, cycling,
and pigmentation (Paus, 2011), it is
particularly interesting to investigate
TYL in a hair research context.
Topically applied TB4 reportedly
enhances hair growth in rats and mice
and stimulates early differentiation of
rat vibrissae epithelial progenitor cells
(Philp et al., 2004), whereas it is un-
known whether TB4 impacts on human
hair growth. Therefore, we wished to
clarify in the current study whether
human scalp HFs express any TPs, and
whether selected TPs exert measurable
effects on human scalp HFs in organ
culture (Kloepper et al., 2010).
Abbreviations: HF, hair follicle; IRS, inner root sheath; ORS, outer root sheath; PTMA, prothymosin alpha;
TB4, thymosin b4; TP, thymic peptide; TYL, thymulin
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TYL, TB4, and PTMA are predominantly
expressed in differentiating epithelial
compartments of the human HF
First, we asked whether human HF
epithelium expresses any defined TPs
on the gene and/or protein level. As no
gene coding for TYL has been identified
(see Supplementary Information S1
online), only TB4 and PTMA gene
transcription could be examined. As
shown in Figure 1a, strong and specific
mRNA signals for both genes were
identified, thus confirming that human
anagen HF epithelium expresses both
TB4 and PTMA.
By immunohistochemistry or immuno-
fluorescence (Supplementary Infor-
mation S2 online), strong PTMA
immunoreactivity was detected in the
hair matrix, the cortex, and inner and
outer root sheaths (IRS and ORS,
respectively) of the lower HF epithe-
lium and, more weakly, in the dermal
papilla (Figure 1b). Interestingly, TB4-
like immunoreactivity was only found
in the nuclei of the IRS, ORS, and
cuticle. Strong TYL immunoreactivity
was detected in Henle’s layer of the
IRS, in the ORS, and in the hair shaft
cortex (Figure 1b).
Expression of these TPs on the gene
and/or protein level suggests the
hypothesis that endogenous, intrafol-
licularly produced TPs are used by
human HFs to regulate some of their
functions.
TYL, thymosin alpha 1, and TB4 exert
subtle, but distinct, effects on human hair
shaft production in vitro
This hypothesis was tested in serum-
free human HF organ culture (Supple-
mentary Information S2 online). We
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Figure 1. Localization of thymulin (TYL), thymo-
sin b4 (TB4), and prothymosin alpha (PTMA)
in the different compartments of the human hair
follicle (HF). (a) Reverse transcription-PCRs to
detect PTMA1 and TB4 transcripts in comple-
mentary (cDNA) derived from RNA from the
epithelial part of female anagen human HFs
follicles. The samples were run on 2% agarose/TAE
gel; PTMA amplicon: 292 bp; TB4 amplicon:
315 bp (þ lanes). The lanes labeled with a ()
indicate the negative control (Neg. ctrl.) reactions
that were run without cDNA. M, DNA size
marker. (b) Exemplary immunohistochemistry and
immunofluorescence results with TYL-, TB4-, or
PTMA-specific antibodies. All three proteins were
detected in the cortex (cx), inner and outer root
sheath (irs and ors, respectively). TYL immuno-
reactivity was PTMA immunoreactivity was also
found in the precortical matrix (pma). TB4 signals
were strictly confined to the nuclei (*) of the mid
and upper regions of the hair follicle not in the
matrix (mx) and the dermal papilla (dp). Negative
controls: experiments conducted without primary
antibody. DAPI, 40-6-diamidino-2-phenylindole;
TAE, Tris-acetate-EDTA. Bars¼ 50mm.
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first studied whether thymosin alpha 1,
a peptide comprising amino acids 2–29
of PTMA, (Supplementary Information
S1 online), TYL, and TB4 modulate hair
shaft production (i.e., the hair shaft
elongation rate) in vitro. Cultivation of
HFs with 10 pg ml1 TYL for 7 days in
three independent experiments from
three different human donors resulted
in an increased hair shaft growth rate
compared with vehicle-treated HFs
(Figure 2a). In contrast, hair shaft
elongation rates of HFs treated with
100 or 1,000 ng ml1 thymosin alpha 1
for 7 days were slightly lower than those
of control HFs (Figure 2a). In TB4-
treated HFs, hair shaft production was
10–20% lower than in the vehicle
control (Figure 2a and Supplementary
Figure S1 online).
TYL prolongs anagen, whereas
TB4 shortens it
Next, we studied by quantitative hair
cycle histomorphometry (Kloepper
et al., 2010) whether the tested TPs
had an effect on the transformation of
anagen VI HFs into the regression stage
of the hair cycle (catagen). This trans-
formation is the clinically most relevant
parameter one can study in HF organ
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Figure 2. Thymic peptides (TPs) differentially modulate human hair growth in vitro. (a) Growth curves of hair follicles treated with two different doses of each
TP (thymulin (TYL) 10: 10 pg ml1 TYL; TYL 100: 100 pg ml1 TYL; thymosin alpha 1 (TA1) 100: 100 ng ml1 TA1; 1,000 ng ml1 TA1; thymosin b4 (TB4) 100:
100 ng ml1 TB4; TB4 1,000: 1,000 ng ml1 TB4). Treatment with 10 pg ml1 TYL led to an increase of hair elongation compared with the control condition
during the treatment period, whereas prothymosin alpha and TB4 treatment slowed down hair growth. Data points in each curve represent mean±SEM. (b) The
hair cycle effects of TPs were assessed by quantitative hair cycle histomorphometry, which included the histochemical analysis of hair cycle–associated hair
pigmentation changes (Masson–Fontana). Note that the anagen–catagen transformation stage of the human hair cycle is characterized by cessation of
proliferation in the matrix and the rapid onset of hair bulb keratinocyte and melanocyte apoptosis (Kloepper et al, 2010). Top row: all experimental conditions
except treatment with 10 pg ml1 TYL led to a shortening of the anagen stage compared with control hair follicles (P¼ 0.06). In the case of 1,000 ng ml1 TB4
and 100 ng ml1 TA1, this effect was the strongest. Bottom row: only treatment with both concentrations of TYL led to a reduction of the hair cycle score (HSC)
compared with vehicle control hair follicles, i.e., the duration of anagen was prolonged. Hair follicles incubated with 1,000 ng ml1 TB4 and 100 and
1,000 ng ml1 TA1 had an average HSC of 200, i.e., the onset of catagen was accelerated. (c) Photographs of exemplary hair follicles submitted to different
experimental conditions as indicated above each photograph. The corresponding HSC values assigned to each hair follicle are below each photograph.
All hair follicles shown in a row are from the same experiment. Bars¼50 mm. (d) Immunofluorescence for the detection of Ki67/TUNEL (Kloepper et al, 2010)
was performed on sections of anagen hair follicles after 7 days of culture under the different treatment conditions. Ki67 and TUNELþ cells were counted in the
marked areas with the highest mitotic activity below Auber’s line (white dotted line, see also Kloepper et al, 2010). In two of three experiments, 10 pg ml1 TYL
led to a 20% increase of Ki67þ cells. In two experiments conducted with 100 pg ml1, TYL increased the number of Ki67þ cells. Treatment with 10 and
100 pg ml1 TYL reduced the number of apoptotic cells in the hair matrix. Bar¼ 50mm. (a–d) Number of independent experiments: 10 pg ml1 TYL and 100 and
1,000 ng ml1 TA1: n¼3 (in total, 36 HFs per treatment condition). Number of independent experiments: 100 pg ml1 TYL, 100 and 1,000 ng ml1 TB4:
n¼ 2 (in total, 24 HFs per treatment condition).
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culture, as any prolongation effect on
anagen would be expected to correlate
with a reduction of telogen effluvium
in vivo (Cotsarelis and Millar, 2001; Paus
and Foitzik, 2004; Kloepper et al., 2010).
Moreover, the effect of each peptide on
the hair cycle was further assessed
by determining the hair cycle score
in each treatment condition (Figure 2b
and c; Supplementary Information
S2 and Supplementary Figure S1b
online).
These analyses showed that HFs
treated with 10 pg ml1 TYL for 7 and
9 days stayed longer in anagen VI than
vehicle-treated controls (Figure 2b,
Supplementary Figure S1b online). By
two-tailed Student’s t-test, these differ-
ences did not come up as significant in
the 7-day treatment group where the
effect of TYL 10 on the distribution of
anagen vs. catagen had a P-value of
0.06. Hair cycle score analysis further
indicated that treatment with TYL for 7
and 9 days inhibited the progression of
HFs from anagen to catagen (Figure 2c,
Supplementary Figure S1b online). This
anagen-prolonging effect of TYL (which
reached significance in the 9 day
cultures) was independently corrobo-
rated by the demonstration that, com-
pared with vehicle controls, treatment
of HFs with 10 pg ml1 TYL for 7 days
increased the number of Ki67þ cells in
the hair matrix of anagen VI HFs, whereas
the number of TUNELþ (i.e., apoptotic)
cells was reduced (Figure 2d).
Despite its slight growth-inhibiting
effect, treatment with 1,000 ng ml1
thymosin alpha 1 for 7 days did not
markedly change HF cycling in vitro in
three independent experiments with HFs
from three different patients (Figure 2d).
Interestingly, there even was a stimula-
tory effect on hair matrix keratino-
cyte proliferation of anagen HFs
(Supplementary Figure S2 online).
Instead, treatment with 1,000 ng ml1
TB4 for 7 days shortened the duration
of anagen and prematurely induced
catagen (Figure 2b and c), yet did not
affect the number of Ki67þ hair
matrix cells, if only anagen HFs were
compared between test and control
groups (Supplementary Figure S2
online).
In conclusion, our pilot study pre-
sents evidence that selected TPs are
produced by human HF epithelium and
operate as direct modulators of human
HF growth; this is—to our knowledge—
previously unreported. In addition,
these initial findings in human scalp
HFs suggest that selected TPs may be
exploited therapeutically for stimulat-
ing, and also for inhibiting, human hair
growth. Namely, we identify TYL as a
clinically interesting candidate hair
growth stimulator. The varying res-
ponse of the limited number of donors
from whom HFs were available for
study suggests substantial interindivi-
dual variations in the response of
human HFs to TP stimulation. Although
the mechanisms of action through
which selected TPs exert their hair
growth–modulatory properties remain
to be dissected (Bock-Marquette et al.,
2004; Mosoian et al., 2010), our data
support the idea that the tested TPs are
indeed important regulators of human
HF biology (see Supplementary Infor-
mation S3 online).
CONFLICT OF INTEREST
FPA is the CEO of Immundiagnostik AG, which
has a commercial interest in kits for the measure-
ment of TPs. The remaining authors state no
conflict of interest.
ACKNOWLEDGMENTS
We gratefully acknowledge Nadine Do¨rwald,
Antje Winter-Keil, and Astrid Becker for excel-
lent technical assistance. This study was sup-
ported in part by a research grant from the
German Federal Ministry of Economics and
Technology (AiF Programme, ProInno-II-Project
KF0670201UL8) to RP.
Natalia Meier1,6, Dorothee Langan1,6,
Heidegard Hilbig2, Eniko¨ Bodo´1,
Nilofer P. Farjo3, Bessam Farjo3,
Franz P. Armbruster4 and Ralf Paus1,5
1Department of Dermatology, University of
Lu¨beck, Lu¨beck, Germany; 2Institute of
Anatomy, University of Leipzig, Leipzig,
Germany; 3Farjo Medical Centre, Manchester,
UK; 4Immundiagnostik AG, Bensheim, Germany
and 5School of Translational Medicine,
University of Manchester, Manchester, UK
E-mail: Ralf.Paus@uksh.de
6These authors are contributed equally to this
work.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online
version of the paper at http://www.nature.com/jid
REFERENCES
Bock-Marquette I, Saxena A, White MD et al.
(2004) Thymosin beta4 activates integrin-
linked kinase and promotes cardiac cell
migration, survival and cardiac repair. Nat-
ure 432:466–72
Brown OA, Sosa YE, Bolognani F et al. (1998)
Thymulin stimulates prolactin and thyrotro-
pin release in an age-related manner. Mech
Ageing Dev 104:249–62
Cotsarelis G, Millar SE (2001) Towards a mole-
cular understanding of hair loss and its
treatment. Trends Mol Med 7:293–301
Folch H, Villegas JV, Leyan V et al. (2010)
Immunohistochemical evidences showing
the presence of thymulin containing cells
located in involuted thymus and in peri-
pheral lymphoid organs. Biol Res 43:
291–8
Hadley AJ, Rantle CM, Buckingham JC (1997)
Thymulin stimulates corticotrophin release
and cyclic nucleotide formation in the rat
anterior pituitary gland. Neuroimmunomo-
dulation 4:62–9
Hannappel E, Huff T (2003) The thymosins.
Prothymosin alpha, parathymosin and beta-
thymosins: structure and function. Vitam
Horm 66:257–96
Kato K, Ikeyama S, Takaoki M et al. (1981)
Epithelial cell components immunoreact
with anti-serum thymic factor (FTS) anti-
bodies: possible association with intermedi-
ate-sized filaments. Cell 24:885–95
Kloepper JE, Sugawara K, Al-Nuaimi Y et al.
(2010) Methods in hair research: how to
objectively distinguish between anagen and
catagen in human hair follcile organ culture.
Exp Dermatol 19:305–12
Moll J, Schmid P, Sansig G et al. (1996) The
pattern of prothymosin alpha gene expres-
sion coincides with that of myc oncogenes
during mouse embryogenesis. Histochem J
28:45–52
Mosoian A, Teixeira A, Burns CS et al. (2010)
Prothymosin-a inhibits HIV-1 via Toll-
like receptor mediated zype I interferon
induction. Proc Natl Acad Sci USA 107:
10178–83
Paus R (2011) A neuroendocrinological pers-
pective on human hair follicle pigmen-
tation. Pigment Cell Melanoma Res 24:
89–106
Paus R, Foitzik K (2004) In search of the ‘‘hair
cycle clock’’: a guided tour. Differentiation
72:489–511
Philp D, Nguyen M, Scheremeta B et al (2004)
Thymosin beta4 increases hair growth by
activation of hair follicle stem cells. FASEB J
18:385–7
Renner D, Schuster D, Heim ME (1986) Experi-
ences using the ‘‘thymu-skin’’ hair cure for
the prevention of alopecia in cytostatic
treatment. Onkologie 5:285–6
Sawaya ME, Shapiro J (2000) Alopecia: unap-
proved treatments or indications. Clin Der-
matol 18:177–86
www.jidonline.org 1519
N Meier et al.
TPs Modulate Human HF Growth
